福瑞股份收盘下跌1.54%，滚动市盈率116.30倍，总市值115.37亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Furuya Co., which operates in the medical device industry, specifically focusing on liver disease-related products [1][2] - As of July 30, Furuya Co. closed at 43.54 yuan, experiencing a decline of 1.54%, with a rolling price-to-earnings (PE) ratio of 116.30 times, significantly higher than the industry average of 55.15 times and the median of 37.48 times [1][2] - The company's total market capitalization stands at 11.537 billion yuan, ranking 107th in the industry based on PE ratio [1][2] Group 2 - Furuya Co. reported a revenue of 330 million yuan for the first quarter of 2025, reflecting a year-on-year increase of 2.35%, while net profit was 28.637 million yuan, showing a decline of 32.97% compared to the previous year [1] - The gross profit margin for the company is reported at 76.76%, indicating a strong profitability despite the drop in net profit [1] - As of July 10, 2025, the number of shareholders for Furuya Co. is 20,833, a decrease of 220 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]